ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8.2 | 3.3 | 1.9 |
| Other income | 2.1 | 0.0 | 0.0 |
| Total income | 10.3 | 3.3 | 1.9 |
| Profit before exceptional items & tax | 2.2 | -2.3 | -0.8 |
| Profit before tax | 2.2 | -2.3 | -0.8 |
| Net profit | 2.2 | -0.6 | -0.8 |
| Operating margin | 21.4% | -69.7% | -42.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +331.60% |
|---|---|
| Operating profit, year on year | +112.50% |
| Operating profit, quarter on quarter | +104.30% |
BSE results filing, NSE: PARMAX. Figures extracted from the filing.
Parmax Pharma Ltd: key numbers
- Share price
- ₹135.00
- Market cap
- ₹50.51 Cr
- Revenue (annual)
- ₹12.11 Cr
- Net profit (annual)
- ₹-4.16 Cr
- P/E (TTM)
- -42.3×Sector 43.8×
- Promoter holding
- 64.66%+33.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Parmax Pharma Ltd
All →Parmax Pharma Board Meeting Date
Parmax Pharma scheduled a board meeting for November 13, 2026 to approve unaudited quarterly and half-year results and shift its registered office. The filing is a prior intimation with no figures.
Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Parmax Pharma Management Change
Parmax Pharma Ltd announced the resignation of Mr. Nikhil Uchat as an Independent Director of the Company, effective October 08, 2026.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd conducted its 32nd Annual General Meeting on September 29, 2026, covering routine business including financial statement adoption and board appointments.
Parmax Pharma Adverse Business Impact
Parmax Pharma reported a major fire incident at its Rajkot plant on September 28, 2026. Two employees were injured, and the company is currently assessing the financial damage.